Ocular Oncology Conference

Jul 18 - 21, 2018 Lisbon, Portugal

Ocular oncogenesis and oncology

This conference — held in partnership with the Champalimaud Foundation and hosted at the Champalimaud Centre for the Unknown, its state-of-the-art treatment and research facility in Lisbon, Portugal — will cover the latest basic and clinical research developments in ocular oncogenesis and oncology, and consider them in the context of the systemic cancer field.

The scientific program will focus on malignant tumors of the eye, including: choroidal malignant melanoma, retinoblastoma and primary vitreoretinal lymphoma, and will cover:

  • epidemiological studies in ocular tumors
  • research into basic pathogenic mechanisms of oncogenesis, including genetics, cell biology and immunology
  • development and evaluation of ocular tumor diagnostics (and classification)
  • results of new human clinical trials for ocular tumor therapies
  • application of advances in systemic oncogenesis and oncology to the ocular field

The conference will include podium sessions, with opening and closing keynote lectures, a tour of the Champalimaud Centre for the Unknown, poster sessions and multiple opportunities for attendees to network. Speakers will be international experts in oncogenesis and oncology, from the Champalimaud Centre for the Unknown and other ophthalmic centers around the globe.

Learning objectives

At the conclusion of the conference, participants will be able to:

  • Describe the current areas of research activity in ocular oncogenesis and oncology.
  • Explain how new research findings have changed the understanding of ocular tumor pathogenesis.
  • Discuss the results of recent clinical research relating to ocular tumor diagnostics, treatments and outcomes.


 Joan O'Brien
 Jacob Pe'er
Joan O’Brien, MD
Scheie Eye Institute 
University of Pennsylvania

Jacob Pe'er, MD, FARVO
Hadassah-Hebrew University Medical Center
Jerusalem, Israel

 J Smith
Justine Smith, FRANZCO, PhD 
Flinders University 
Adelaide, Australia
David Wilson, MD 
Casey Eye Institute 
Oregon Health & Science University

Champalimaud Foundation Scientific Program Liaison 

Antonio Parreira
Antonio Parreira, MD, PhD
Champalimaud Foundation
Lisbon, Portugal

 Guests of Honor

Cunha-Vaz Martine Jager
Jose´ Cunha-Vaz, MD, PhD
Coimbra, Portugal
Martine Jager, MD, PhD, FARVO
Leiden University Medical Center
Leiden, Netherlands

Opening Keynote
Bettina Ryll, MD, PhD
Founder, Melanoma Patient Network Europe 

Dr. Ryll holds a medical degree from the Free University of Berlin, Germany and a PhD in Biomedical Sciences from University College London, UK

After losing her husband to melanoma, she founded the Melanoma Patient Network Europe and developed a special interest in patient-centric clinical research, in particular, innovative trial designs and novel drug development concepts, such as MAPPS (medicines' adaptive pathways to patients), previously known as Adaptive Licensing. Lately, her focus has moved to sustainable healthcare models ensuring access to innovative therapies for cancer patients and incentives for sustainable innovation.

Dr. Ryll is involved in numerous initiatives promoting evidence-based advocacy. She is fascinated by the enormous potential and capacity of patient networks to both educate and support patients as well as to capture data at the primary data source - the patients themselves - and to generate evidence at a granular level non-accessible to outsiders. 

Phoenix research labs